Article Text

other Versions

PDF
Patterns of ALK expression in different human cancer types
  1. Pierre Tennstedt1,
  2. Gundula Strobel2,
  3. Charlotte Bölch2,
  4. Tobias Grob2,
  5. Sarah Minner2,
  6. Sawinee Masser2,
  7. Ronald Simon2
  1. 1Martini-Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  2. 2Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  1. Correspondence to Dr Ronald Simon, Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; r.simon{at}uke.de

Abstract

Aims Oncogenic gene fusions involving the anaplastic lymphoma kinase (ALK) tyrosine kinase have been identified in several haematopoietic and sporadically also in solid tumour types. Preliminary results from clinical trials suggest that patients with ALK fusion positive cancers might optimally benefit from the tyrosine kinase inhibitor crizotinib, but a comprehensive analysis of solid tumour types for ALK fusion and fusion associated expression is lacking.

Methods In order to identify human solid cancers carrying ALK alterations, we performed real-time PCR screening of 1000 tumour samples representing 29 different tumour entities. ALK-positive samples were then transferred into a tissue microarray format and subjected to ALK break-apart fluorescence in situ hybridisation (FISH) analysis and ALK immunohistochemistry (IHC) analysis.

Results ALK expression was detected by real-time PCR in 260 of 896 (29%) interpretable tumour samples. FISH analysis was successful in 189 of 260 arrayed cancers but did not detect ALK rearrangement. There was also no ALK expression detectable by IHC.

Conclusions Different levels of ALK expression can be found in various cancer types using sensitive methods like real-time PCR. However, such low-level expression is independent from oncogenic ALK fusions and cannot be detected with less-sensitive methods like IHC. ALK fusion is a rare event in human solid cancers.

  • CANCER GENETICS
  • HISTOPATHOLOGY
  • IMMUNOHISTOCHEMISTRY
  • IN SITU HYBRIDISATION
  • MOLECULAR PATHOLOGY

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.